Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ RCKT′s IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +++ ROCKET PHARMACEUTICALS Aktie +3,61%

BIOCRYST Aktie

 >BIOCRYST Aktienkurs 
7.65 EUR    +0.6%    (Tradegate)
Ask: 7.714 EUR / 500 Stück
Bid: 7.56 EUR / 500 Stück
Tagesumsatz: 2917 Stück
Realtime Kurs von 8 bis 22 Uhr!
BIOCRYST Aktie über LYNX handeln
>BIOCRYST Performance
1 Woche: -8,8%
1 Monat: -19,9%
3 Monate: +13,5%
6 Monate: +4,5%
1 Jahr: +25,6%
laufendes Jahr: +4,5%
>BIOCRYST Aktie
Name:  BIOCRYST PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09058V1035 / 896047
Symbol/ Ticker:  BO1 (Frankfurt) / BCRX (NASDAQ)
Kürzel:  FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX
Index:  -
Webseite:  https://www.biocryst.com/
Marktkapitalisierung:  1940 Mio. EUR
Umsatz:  436.49 Mio. EUR
EBITDA:  32.48 Mio. EUR
Gewinn je Aktie:  -0.199 EUR
Schulden:  718.95 Mio. EUR
Liquide Mittel:  255.83 Mio. EUR
Umsatz-/ Gewinnwachstum:  56.9% / -
KGV/ KGV lG:  - / 62.89
KUV/ KBV/ PEG:  4.56 / 55.19 / -
Gewinnm./ Eigenkapitalr.:  -10.62% / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  BIOCRYST
Letzte Datenerhebung:  01.07.25
>BIOCRYST Eigentümer
Aktien: 209.25 Mio. St.
f.h. Aktien: 207.07 Mio. St.
Insider Eigner: 1.15%
Instit. Eigner: 85.57%
>BIOCRYST Peer Group

 
01.07.25 - 15:30
 IN BRIEF: BioPharma Credit to be repaid following disposal by BioCryst (Alliance)
 
BioPharma Credit PLC - London-based closed-ended investment company focused on the life sciences industry - Investment Manager Pharmakon Advisors LP notes that BioCryst Pharmaceuticals Inc......
27.06.25 - 13:39
 BioCryst to sell European Orladeyo business for up to $264M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.06.25 - 13:06
 BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million (GlobeNewswire EN)
 
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones—...
25.06.25 - 19:45
 BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
 
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
16.06.25 - 13:03
 BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI (GlobeNewswire EN)
 
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—...
13.06.25 - 13:03
 ORLADEYO® (berotralstat) Approved in Colombia (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older....
06.06.25 - 13:03
 BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries (GlobeNewswire EN)
 
ORLADEYO® (berotralstat) now reimbursed in the Netherlands ORLADEYO® (berotralstat) now reimbursed in the Netherlands...
04.06.25 - 19:45
 BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
 
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out....
03.06.25 - 13:03
 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
02.06.25 - 13:03
 BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.  ...
30.05.25 - 13:03
 BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages (GlobeNewswire EN)
 
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life...
27.05.25 - 13:03
 BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...
26.05.25 - 17:30
 Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here′s is How to Trade (Zacks)
 
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
16.05.25 - 13:03
 BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations....
14.05.25 - 15:30
 BioCryst′s Orladeyo up for FDA review in pediatric HAE patients (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 19:45
 Why BioCryst (BCRX) Might be Well Poised for a Surge (Zacks)
 
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....
08.05.25 - 19:45
 What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? (Zacks)
 
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out....
08.05.25 - 17:30
 Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? (Zacks)
 
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
05.05.25 - 18:57
 BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 16:42
 BioCryst stock jumps on raised guidance, strong Q1 report (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Kasten voll Lügen wird nicht durchs Stadttor gelassen. - Sprichwort China
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!